The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.EBI
Novartis Institutes For Biomedical Research
Isocoumarins, miraculous natural products blessed with diverse pharmacological activities.EBI
Quaid-I-Azam University
Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5.EBI
Universidade Federal Fluminense
The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.EBI
Campus
Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.EBI
Queensland University of Technology
Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.EBI
Universidade Federal Do Abc
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.EBI
Universit£
1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.EBI
Universit£
Isomannide derivatives as new class of inhibitors for human kallikrein 7.EBI
Universidade Federal Do Tri£Ngulo Mineiro
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University of Florida
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.EBI
Universidade Federal Do Tri£Ngulo Mineiro
Phage Display Selected Cyclic Peptide Inhibitors of Kallikrein-Related Peptidases 5 and 7 and Their EBI
Ecole Polytechnique F�D�Rale De Lausanne (Epfl)
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.EBI
Glaxosmithkline R&D
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.EBI
Glaxosmithkline
Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.EBI
Glaxosmithkline R&D
Amino Acid Scanning at P5' within the Bowman-Birk Inhibitory Loop Reveals Specificity Trends for Diverse Serine Proteases.EBI
The University of Queensland
Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.EBI
The University of Queensland
3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.EBI
Universidade Federal Fluminense
Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors.EBI
Asubio Pharma
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.EBI
German Cancer Research Center (Dkfz)
Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors.EBI
Asubio Pharma
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.EBI
Bicycle Therapeutics